Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction~* Deemed unresectable and not a candidate for potentially curative treatment (e.g., surgical resection or combined modality therapy)~  * At least 4 weeks since prior abdominal exploration with resection (3 weeks without resection)~ * No other more conventional forms of therapy available with a reasonable chance of cure or significant palliation~* Measurable disease\*~  * The following are not considered measurable disease:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Lymphangitis cutis/pulmonis~   * Abdominal masses that are not confirmed and followed by imaging~   * Cystic lesions NOTE: \*Patients having only lesions measuring ≥ 1 cm to \< 2 cm must use spiral CT scan for all tumor assessments.~* No untreated or treated but symptomatic CNS metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than upper limit of normal (ULN)~* AST no greater than 2.5 times ULN if alkaline phosphatase is less than ULN OR~* Alkaline phosphatase no greater than 4 times ULN if AST less than ULN~Renal~* Creatinine normal~* Creatinine clearance at least 60 mL/min~Cardiovascular~* No New York Heart Association class III or IV heart disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Ability to swallow capecitabine~* No prior anaphylactic reaction to any taxane~* No prior severe reaction to fluoropyrimidine~* No prior poor tolerance to capecitabine~* No known sensitivity or poor tolerance to fluorouracil~* No known dihydropyrimidine dehydrogenase deficiency~* No uncontrolled infection~* No uncontrolled seizure disorder~* No chronic debilitating disease~* No peripheral neuropathy of any etiology greater than grade 1~* No diabetes mellitus~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell carcinoma or adequately treated noninvasive carcinoma~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior immunotherapy or biologic therapy for recurrent or metastatic disease~* No concurrent biologic therapy~Chemotherapy~* No prior chemotherapy for recurrent or metastatic disease except for the following:~  * Adjuvant chemotherapy after complete resection of the original tumor~ * Neoadjuvant chemotherapy followed by surgical resection of the original tumor~* No other concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy except for the following:~  * Adjuvant radiotherapy after complete resection of the original tumor~ * Neoadjuvant radiotherapy followed by surgical resection of the original tumor~* No prior radiotherapy to 25% or more of the bone marrow~* More than 4 weeks since prior radiotherapy~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~* No prior organ allograft~Other~* No concurrent brivudine or sorivudine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- docetaxel + capecitabine (Type: EXPERIMENTAL): Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration.

Based on this trial design, predict the completion outcome and termination type (if applicable).